Lacosamide Eg (Lacosamide)

Lacosamide is an anti‑epileptic drug used to control focal seizure activity.

• Partial‑onset seizures (adults): Reduces seizure frequency when added to existing therapy in adult epilepsy patients.
• Partial‑onset seizures (pediatric ≥4 years): Provides adjunctive seizure control in children four years of age and older.
• Refractory focal epilepsy: Serves as an adjunctive option for patients whose seizures are not adequately controlled by other medications.

• Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes, which stabilizes hyper‑excitable neurons and diminishes repetitive firing. This modulation reduces the propagation of epileptic discharges without affecting the fast inactivation phase, contributing to its anticonvulsant effect.

Lacosamide may cause a range of adverse reactions.

Common Side Effects

• Dizziness: Sensation of light‑headedness or unsteadiness.
• Fatigue: Persistent tiredness or lack of energy.
• Nausea: Stomach upset often accompanied by an urge to vomit.
• Headache: Mild to moderate pain in the head region.
• Blurred vision: Temporary loss of visual clarity.

Serious or Rare Side Effects

• Cardiac conduction abnormalities: Prolongation of the PR interval that may lead to arrhythmias.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Suicidal thoughts or behavior: Emergence of depressive symptoms or self‑harm ideation.

Before initiating therapy, consider the following safety measures.

• Cardiac conduction: Obtain baseline ECG and monitor for PR‑interval changes.
• Renal impairment: Assess renal function; dose adjustment may be required.
• Pregnancy: Safety not established; use only if potential benefit outweighs risk.
• Driving and operating machinery: Counsel patients about possible dizziness or visual disturbances.
• Concomitant medications: Review all drugs for potential interactions that may affect cardiac or CNS safety.
• Store below 25°C: Keep in the original packaging, protect from moisture and direct sunlight.

Lacosamide can interact with several medicines, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): May increase lacosamide plasma concentrations.
• Other sodium‑channel blockers (e.g., carbamazepine, phenytoin): Heightened risk of cardiac conduction effects.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inducers (e.g., rifampin, carbamazepine): May reduce lacosamide levels.
• Concomitant use with antihypertensives: Potential additive hypotensive effect.
• Alcohol or CNS depressants: May enhance sedation or dizziness.